The hepatitis C virus (HCV) is a leading cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma and is also a common indication for liver transplantation. Interferon alfa monotherapy leads to a sustained virologic response in only 10% to 15% of HCV-infected patients. The sustained virologic response rates can be increased to approximately 40% with interferon alfa-2b and ribavirin combination therapy for up to 48 weeks. However, recent clinical trials demonstrated that pegylated interferon in combination with ribavirin can improve the response rates even further, with more than 50% of patients having a sustained virologic response to treatment. Although new therapies are emerging, significant progress must be made to reduce the morbidity and mortality from HCV infection.
1. Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL. Deaths: final data for 2000. Natl Vital Stat Rep. 2002;50:1-119.
2.
2. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47:1-39.
3.
3. American Gastroenterological Association. The Burden of Gastrointestinal Diseases. Bethesda, Md: American Gastroenterological Association; 2001.
4.
4. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med. 2001;161:2231-2237.
5.
5. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36:S30-S34.
6.
6. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-1511.
7.
7. Alter MJ. Epidemiology of hepatitis C. Hepatology. 1997;26:62S-65S.
8.
8. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562.
9.
9. Bukh J, Miller RH. Diagnostic and clinical implications of the different genotypes of hepatitis C virus. Hepatology. 1994;20: 256-259.
10.
10. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis. 1995;15:41-63.
11.
11. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of the hepatitis C virus. Princess Takamatsu Symp. 1995;25:75-91.
12.
12. Blatt LM, Mutchnick MG, Tong MJ, et al. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat. 2000;7:196-202.
13.
13. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis. 1995;15:5-14.
14.
14. Alter MJ. Epidemiology of hepatitis C. Eur J Gastroenterol Hepatol. 1996;8:319-323.
15.
15. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol. 1999;31(suppl 1):88-91.
16.
16. Delage G, Infante-Rivard C, Chiavetta JA, Willems B, Pi D, Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: results of a case-control study. Gastroenterology. 1999;116:893-899.
17.
17. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol. 2003;36:47-53.
18.
18. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA. 1989;262:1201-1205.
19.
19. Mendenhall CL, Moritz T, Rouster S, et al. Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. Am J Gastroenterol. 1993;88:1022-1026.
20.
20. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334:1691-1696.
21.
21. Brau N, Bini EJ, Shahidi A, et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol. 2002;97:2071-2078.
22.
22. Ernst E, Sherman KJ. Is acupuncture a risk factor for hepatitis? Systematic review of epidemiological studies. J Gastroenterol Hepatol. 2003;18:1231-1236.
23.
23. Bini EJ. Hepatitis C in veterans. Current Hepatitis Reports. 2003;2:108-115.
24.
24. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31(suppl 1):9-16.
25.
25. Anonymous. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: 2002— June 10-12, 2002. Hepatology. 2002;36:S3-S20.
26.
26. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26:15S-20S.
27.
27. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology. 2002;36:S179-S184.
28.
28. Barkhuizen A, Bennett RM. Hepatitis C infection presenting with rheumatic manifestations. J Rheumatol. 1997;24:1238-1239.
29.
29. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol. 1999;94:1355-1360.
30.
30. Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. JViralHepat. 2002;9:295-303.
31.
31. Wessely S, Pariante C. Fatigue, depression and chronic hepatitis C infection. Psychol Med. 2002;32:1-10.
32.
32. Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol. 2001;32:413-417.
33.
33. Cordoba J, Flavia M, Jacas C, et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol. 2003;39:231-238.
34.
34. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27:209-212.
35.
35. Carithers RL Jr, Sugano D, Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci. 1996;41:75S-80S.
36.
36. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999;29:264-270.
37.
37. Seeff LB. Natural history of hepatitis C. Am J Med. 1999;107:10S-15S.
38.
38. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 1991;14:969-974.
39.
39. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744-749.
40.
40. Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26: 21S-28S.
41.
41. Seeff LB. The natural history of hepatitis C-A quandary. Hepatology. 1998;28:1710-1712.
42.
42. Seeff LB. Dilemma of the natural history of hepatitis C. J Gastroenterol Hepatol. 1999;14:199-201.
43.
43. Seeff LB. Why is there such difficulty in defining the natural history of hepatitis C?Transfusion. 2000;40:1161-1164.
44.
44. Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 1996;8:324-328.
45.
45. Tong MJ, El Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332:1463-1466.
46.
46. Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology. 1998;27:1717-1722.
47.
47. Wiley TE, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805-809.
48.
48. Benhamou Y, Bochet M, Di M, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30: 1054-1058.
49.
49. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzalez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol. 1999;31(suppl 1):119-123.
50.
50. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology. 1997;26:34S-38S.
51.
51. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum1999;42:2204-2212.
52.
52. Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore). 2000;79:47-56.
53.
53. Durand JM. Extrahepatic manifestations of hepatitis C virus infection. Am J Gastroenterol. 1997;92:1402.
54.
54. El Serag HB, Hampel H, Yeh C, Rabeneck L. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002;36:1439-1445.
55.
55. Ferri C, La Civita L, Zignego AL. Extrahepatic manifestations of hepatitis C virus infection. AnnInternMed. 1996;125:344.
56.
56. Gordon SC. Extrahepatic manifestations of hepatitis C. Dig Dis. 1996;14:157-168.
57.
57. Hadziyannis SJ. The spectrum of extrahepatic manifestations in hepatitis C virus infection. JViralHepat. 1997;4:9-28.
58.
58. Hoogenraad TU, Jansen GH, van Hattum J. Extrahepatic manifestations of hepatitis C virus infection. AnnInternMed. 1996;125:345.
59.
59. Zignego AL, Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol. 1999;31:369-376.
60.
60. Carithers RL Jr, Marquardt A, Gretch DR. Diagnostic testing for hepatitis C. Semin Liver Dis. 2000;20:159-171.
61.
61. Fried MW. Diagnostic testing for hepatitis C: practical considerations. Am J Med. 1999;107:31S-35S.
62.
62. Gretch DR. Diagnostic tests for hepatitis C. Hepatology. 1997;26:43S-47S.
63.
63. Pawlotsky JM. Diagnostic tests for hepatitis C. J Hepatol. 1999;31(suppl 1):71-79.
64.
64. Schiff ER, de Medina M, Kahn RS. New perspectives in the diagnosis of hepatitis C. Semin Liver Dis. 1999;19(suppl 1):3-15.
65.
65. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
66.
66. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 1997;26:71S-77S.
67.
67. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998;28:1121-1127.
68.
68. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med. 1986;315:1575-1578.
69.
69. Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol. 1999;31(suppl 1):152-159.
70.
70. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26:83S-88S.
71.
71. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778-789.
72.
72. Lindsay KL, Davis GL, Schiff ER, et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology. 1996;24:1034-1040.
73.
73. Shiffman ML. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis. 1999;19(suppl 1):25-33.
74.
74. Anonymous. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997;26:2S-10S.
75.
75. Snell NJ. Ribavirin: current status of a broad spectrum antiviral agent. Expert Opin Pharmacother. 2001;2:1317-1324.
76.
76. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 1992; 16:649-654.
77.
77. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. AnnInternMed. 1995;123:897-903.
78.
78. Hoofnagle JH, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie AM. Prolonged therapy of chronic hepatitis C with ribavirin. J Viral Hepat. 1996;3:247-252.
79.
79. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology. 1997;26: 473-477.
80.
80. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
81.
81. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
82.
82. Zeuzem S, Herrmann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology. 2001;120:1438-1447.
83.
83. Hadziyannis SJ, Papatheodoridis GV. Recent peginterferon and ribavirin combination trials. Current Hepatitis Reports. 2004;3:30-37.
84.
84. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon Alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
85.
85. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
86.
86. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl JMed. 2000;343:1673-1680.
87.
87. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
88.
88. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
89.
89. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. AnnInternMed. 2004;140:346-355.
90.
90. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. AnnInternMed. 1996;125:658-668.
91.
91. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-2271.
92.
92. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003;124:1711-1719.
93.
93. Gaeta GB, Precone DF, Felaco FM, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in “real world” patients with chronic hepatitis C. Aliment Pharmacol Ther. 2002;16:1633-1639.
94.
94. Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38-47.
95.
95. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26:112S-121S.
96.
96. Neary MP, Cort S, Bayliss MS, Ware JE Jr. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis. 1999;19(suppl 1):77-85.
97.
97. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002;35:704-708.
98.
98. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171.
99.
99. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. AnnInternMed. 2002;136:288-292.
100.
100. Muir AJ, Provenzale D. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol. 2002;34:268-271.
101.
101. Cawthorne CH, Rudat KR, Burton MS, et al. Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol. 2002;97:149-155.
102.
102. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology. 2000;32:630-634.
103.
103. Reusser P. Antiviral therapy: current options and challenges. Schweiz Med Wochenschr. 2000;130:101-112.
104.
104. Davis GL, Nelson DR, Reyes GR. Future options for the management of hepatitis C. Semin Liver Dis. 1999;19(suppl 1):103-112.
105.
105. Chou R, Clark EC, Helfand M. Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. AnnInternMed. 2004;140:465-479.
106.
106. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-782.
